Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
36.3M
-
Shares change
-
+1.82M
-
Total reported value, excl. options
-
$349M
-
Value change
-
+$17.9M
-
Put/Call ratio
-
0.38
-
Number of buys
-
49
-
Number of sells
-
-35
-
Price
-
$9.63
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q3 2023
121 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q3 2023.
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.3M shares
of 50M outstanding shares and own 72.53% of the company stock.
Largest 10 shareholders include TANG CAPITAL MANAGEMENT LLC (3.44M shares), TCG Crossover Management, LLC (3.4M shares), Frazier Life Sciences Management, L.P. (3.24M shares), VR Adviser, LLC (2.92M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (2.42M shares), Saturn V Capital Management LP (1.81M shares), VANGUARD GROUP INC (1.73M shares), Boxer Capital, LLC (1.65M shares), BlackRock Inc. (1.64M shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (1.06M shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.